Long-term safety of eplontersen in ATTR patients
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This study follows people who already took part in an earlier trial (D8450R00003) to see how safe eplontersen is over the long term. It also includes people who had a liver transplant or severe liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were in the earlier D8450R00003 study and agreed to have your data used for future research.
- You either started eplontersen within the past year before joining the D8450R00003 study, or you started a different ATTR treatment during that study.
- You have not taken eplontersen for more than a year before joining the D8450R00003 study.
- You did not take part in any other ATTR treatment study in the 12 months before joining the D8450R00003 study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
This study tracks the safety of eplontersen during pregnancy and breastfeeding by collecting reports from people who have taken it. It helps doctors understand any risks to the baby or mother.
This study evaluates the long-term safety and effectiveness of the study drug ALXN2220 in people with transthyretin amyloid cardiomyopathy. It is an extension of a previous trial, so if you completed the earlier study, you may be able to continue receiving the treatment and be monitored for a longer period.
This trial studies the long-term safety of luspatercept (ACE-536) in people who already took part in an earlier luspatercept study. It mainly helps doctors better understand ongoing side effects and overall safety over time.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
Hear when a new Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.